Dr. Clifford Weiss, the Director of the Johns Hopkins Vascular Anomalies Center, shares his expertise on hereditary hemorrhagic telangiectasia (HHT) and pulmonary AVMs. He discusses the critical role of early diagnosis and multidisciplinary teams in effective patient care. The conversation highlights evolving guidelines for intervention, the intricacies of embolization techniques, and the importance of genetic testing. Dr. Weiss also sheds light on innovative treatments and ongoing challenges in managing HHT, showcasing the impact of specialized care on patient outcomes.